Share on StockTwits

Protalix BioTherapeutics (NYSE:PLX) was the target of a large drop in short interest in May. As of May 30th, there was short interest totalling 5,962,058 shares, a drop of 1.3% from the May 15th total of 6,041,735 shares, Analyst Ratings Net reports. Based on an average daily volume of 176,374 shares, the days-to-cover ratio is presently 33.8 days. Currently, 8.2% of the shares of the stock are short sold.

A number of research firms have recently commented on PLX. Analysts at JPMorgan Chase & Co. cut their price target on shares of Protalix BioTherapeutics from $8.00 to $7.00 in a research note on Tuesday, May 13th. They now have an “overweight” rating on the stock. Separately, analysts at Jefferies Group reiterated a “hold” rating on shares of Protalix BioTherapeutics in a research note on Monday, May 12th. They now have a $4.25 price target on the stock, down previously from $5.50. Finally, analysts at Zacks downgraded shares of Protalix BioTherapeutics from a “neutral” rating to an “underperform” rating in a research note on Wednesday, April 9th. They now have a $4.30 price target on the stock.

Protalix BioTherapeutics (NYSE:PLX) opened at 3.80 on Thursday. Protalix BioTherapeutics has a 1-year low of $3.70 and a 1-year high of $5.72. The stock has a 50-day moving average of $3.93 and a 200-day moving average of $4.30. The company’s market cap is $352.2 million.

Protalix BioTherapeutics (NYSE:PLX) last issued its quarterly earnings data on Thursday, May 22nd. The company reported ($0.08) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.07) by $0.01. Analysts expect that Protalix BioTherapeutics will post $-0.22 EPS for the current fiscal year.

Protalix BioTherapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.